ClinicalTrials.gg
RecruitingNCT07469111Updated Mar 13, 2026

Effects Of Low-Load Blood Flow Restriction Training Of The Upper Extremity In Patients With Chronic Obstructive Pulmonary Disease

An interventional study of Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise and Sham Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise in Chronic Obstructive Pulmonary Disease (COPD) and Blood Flow Restriction Training (BFRT), sponsored by Inonu University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-13.

Sponsored by Inonu University · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey — 58 open to participants now, 68 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Turkey.

Planned enrollment
157th of 188
36 · median 72
Started
2026
with 15 others
No phase
122 of 248
33 open now
Primary completion
2026-12
later than 52 of 67 live
Registered
235th of 248
by date

Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, this one is the 157th largest by planned enrollment of the 188 interventional ones that give a count, is one of 16 that started in 2026, is one of 122 with no phase, reaches primary completion later than 52 of the 67 other live ones, and was the 235th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

58 of the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey are open now. Recruiting first, the newest first:

52 more — sign in →

All 58 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, or all of them as a file.
02

Study summary

Chronic Obstructive Pulmonary Disease (COPD) is characterized by persistent airflow limitation, progressive dyspnea, and peripheral muscle dysfunction, significantly impairing functional capacity and quality of life. Although the combined implementation of aerobic and resistance exercises is recommended in pulmonary rehabilitation programs, early-onset ventilatory limitation in individuals with COPD often hinders tolerance to high exercise intensities. This limitation increases the need for alternative exercise approaches targeting peripheral muscle adaptations. Low-load blood flow restriction training (LL-BFRT), which enables improvements in muscle strength with low mechanical loads, has emerged as a potential option for this patient population. However, evidence regarding the effects of LL-BFRT in individuals with COPD-particularly on upper extremity muscles-remains limited.

The aim of this study is to comparatively investigate the effects of LL-BFRT and sham-BFRT, both administered in addition to an aerobic exercise program in individuals diagnosed with stage II and III COPD, on upper extremity muscle strength, upper extremity functional capacity, activities of daily living performance, quality of life, functional exercise capacity, muscle oxygenation, and respiratory parameters. The study is designed as a randomized controlled, single-blind, quasi-experimental interventional trial.

The expected outcomes are that LL-BFRT may enhance upper extremity muscle strength and functional capacity, improve activities of daily living and quality of life, and increase exercise tolerance due to its applicability at low mechanical loads. Furthermore, findings related to muscle oxygenation and respiratory parameters are anticipated to provide clinical evidence regarding the physiological effects of LL-BFRT on peripheral muscle adaptations. These results are expected to guide the integration of LL-BFRT as an alternative and safe approach in upper extremity exercise prescription within pulmonary rehabilitation programs, support clinical decision-making processes, and establish a scientific foundation for future research.

Read the detailed description

Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and irreversible airflow limitation resulting from airway and/or alveolar abnormalities, usually caused by prolonged exposure to noxious particles or gases (1). COPD represents one of the leading causes of mortality among chronic respiratory diseases and is recognized as a major global health problem, affecting approximately 10% of the adult population, with an increasing incidence associated with population aging. According to the 2017 Global Burden of Disease (GBD) Study, the global mortality rate attributable to COPD was 41.9 deaths per 100,000 population, accounting for 5.7% of all-cause mortality. The mortality rate was reported as 46.7 per 100,000 in men and 37.0 per 100,000 in women (2).

The progressive and persistent airflow limitation in COPD, together with reduced parenchymal elasticity, increases ventilatory demand and imposes an excessive load on the respiratory muscles. Hyperinflation further reduces the effective contractile range of these muscles, creating a vicious cycle in which mechanoreceptor stimulation enhances ventilatory drive and exacerbates dyspnea. Increased dyspnea and impaired respiratory muscle function limit the performance of activities of daily living (ADLs), leading to substantial reductions in physical performance (3).

Skeletal muscle dysfunction is a frequent systemic manifestation of COPD. Reductions in peripheral muscle strength involving the upper and lower extremities as well as the trunk significantly limit exercise capacity and functional performance, negatively affecting overall health status. Importantly, impaired muscle strength has been identified as a strong predictor of morbidity, mortality, disability, and exacerbation risk, independent of the degree of airway obstruction (4).

During upper extremity activities, individuals with COPD frequently experience marked dyspnea and dynamic hyperinflation, which significantly restrict functional independence and highlight the clinical importance of upper extremity functional capacity (5). Compared with healthy peers, individuals with COPD demonstrate reduced performance during upper limb activities and report substantial difficulty. This limitation is partly attributable to altered respiratory mechanics, as upper extremity muscles also function as accessory respiratory muscles. Consequently, dyspnea intensifies during upper limb activity, often leading to premature termination of exercise (6).

Given the dyspnea-inducing nature of upper extremity use and its negative impact on activity tolerance, preserving and improving upper extremity function constitutes a critical rehabilitation target in COPD. Indeed, as emphasized in the most recent joint official statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS), the inclusion of upper extremity exercise training in pulmonary rehabilitation programs is strongly supported for individuals with COPD (7).

Pulmonary rehabilitation programs commonly incorporate aerobic modalities such as arm ergometry, as well as resistance-based approaches using multi-station systems, elastic bands, or free weights to target upper extremity function (8). Although aerobic exercise forms the cornerstone of pulmonary rehabilitation, its effects on muscle strength and mass are considered limited. Therefore, combined aerobic and resistance exercise approaches are recommended to more effectively address peripheral muscle dysfunction (9).

However, whether currently tolerated training intensities-often limited by ventilatory constraints-are sufficient to optimally target peripheral muscle dysfunction remains controversial. Both the ATS and ERS have highlighted the need for innovative rehabilitation strategies capable of targeting peripheral muscle dysfunction at lower mechanical loads (10). Traditional moderate-to-high intensity resistance training may be effective but is often poorly tolerated in individuals with COPD due to dyspnea, early fatigue, and ventilatory limitation, thereby limiting adherence and long-term participation (11).

In this context, low-load blood flow restriction training (LL-BFRT) has emerged as a promising alternative. Despite the use of low mechanical loads, LL-BFRT induces localized ischemia and increased metabolic stress, leading to significant gains in muscle strength and hypertrophy. This method may represent a viable option for individuals with COPD who are unable to tolerate high mechanical loads (12).

Although evidence supporting LL-BFRT primarily derives from studies conducted in healthy individuals and predominantly targeting lower extremity muscles (12-14), data regarding its application to upper extremity muscles in individuals with COPD remain limited. Considering that upper limb activities impose greater ventilatory demand and trigger dyspnea earlier, the potential advantages of LL-BFRT in this region warrant investigation. This research gap underscores the necessity of evaluating the effectiveness of LL-BFRT-based upper extremity resistance training in COPD.

Aim of the Study The aim of this study is to comparatively investigate the effects of LL-BFRT and sham-BFRT, administered in addition to an aerobic exercise program, on upper extremity muscle strength, upper extremity functional capacity, performance of activities of daily living, quality of life, functional exercise capacity, muscle oxygenation, and pulmonary function parameters in individuals diagnosed with stage II and III COPD.

Interventions Participants in both groups will undergo an exercise program twice weekly for 8 weeks.

Both groups will perform upper extremity aerobic exercise using an arm cycle ergometer. Each session will begin with a 5-minute warm-up at 0 Watts, followed by 20 minutes of aerobic exercise at 60-70% of age-predicted maximum heart rate. Initial resistance will be set between 35-50 Watts and maintained within this range according to individual exercise tolerance. Dyspnea will be monitored using the Modified Borg Scale. A 5-minute cool-down at 0 Watts will follow the aerobic phase.

Intervention Group (LL-BFRT) In addition to aerobic exercise, participants in the intervention group will receive LL-BFRT. A pneumatic cuff will be placed proximally on the upper extremity. Occlusion pressure will be set at 30-40% of arterial occlusion pressure (AOP). Resistance will be set at 30% of one-repetition maximum (1RM). Exercises will follow a standardized 4-set protocol (30-15-15-15 repetitions) with 45-second inter-set rest periods, during which cuff pressure will be maintained.

Targeted muscle groups will include the biceps brachii, triceps brachii, and anterior deltoid. After completion of each exercise, cuff pressure will be released for a 5-minute reperfusion period before proceeding to the next exercise. Dyspnea will be closely monitored using the Modified Borg Scale, and exercise will be terminated if dyspnea reaches ≥6, indicating exercise intolerance.

Control Group (Sham-BFRT) Participants in the control group will receive the same aerobic exercise protocol and identical resistance exercise structure. However, cuff pressure during sham-BFRT will be set at a level insufficient to produce therapeutic blood flow restriction.

Assessments Demographic data including age, sex, height, and weight will be recorded. Body mass index (BMI) will be calculated. Smoking history will be documented in pack-years. Disease duration and COPD stage (according to GOLD classification) will be determined from medical records. Oxygen therapy and inhaled treatment use will be recorded. Exacerbation frequency, defined as the number of exacerbations and hospital admissions within the past 12 months, will also be documented.

This study is expected to provide evidence regarding the clinical efficacy and physiological mechanisms of LL-BFRT in improving upper extremity function in individuals with COPD and to inform exercise prescription within pulmonary rehabilitation programs.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Blood Flow Restriction Training (BFRT)

Keywords

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Los Load Resistance Exercise
  • Upper Extremity Function
  • Muscle Strength
  • Blood Flow Restriction Training (BFRT)
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 40-80 years with stage 2 and 3 diagnosed according to GOLD criteria

    • Clinically stable COPD (no exacerbation in the last 6 weeks)
    • Stable medical treatment for at least 4 weeks
    • No orthopedic or neurological problems that would prevent them from performing upper extremity exercises
    • Resting SpO2 ≥ 88%
    • Able to understand and follow verbal instructions in Turkish
    • Individuals with a Scale (MoCa) score ≥ 24 will be included.

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension

    • Severe arrhythmia
    • Recent MI
    • Deep vein thrombosis
    • Peripheral vascular disease
    • Presence of infection or open wound
    • Having undergone upper extremity surgery within the last 6 months
    • Cognitive impairment or cooperation problems will be among the exclusion criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants will receive an 8-week upper extremity aerobic exercise program combined with low-load blood flow restriction training targeting upper extremity muscles.

    Other: Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise

  • Sham comparator
    Control Group

    Participants will receive the same 8-week upper extremity aerobic exercise program combined with sham blood flow restriction training with non-therapeutic cuff pressure.

    Other: Sham Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise

Interventions

  • OtherLow-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise

    Participants will undergo an 8-week upper extremity aerobic exercise program combined with low-load blood flow restriction training (LL-BFRT). The aerobic exercise will be performed using an arm cycle ergometer at 60-70% of age-predicted maximum heart rate for 20 minutes, preceded and followed by 5 minutes of unloaded cycling. In addition, LL-BFRT will be applied to the proximal upper extremity with a pneumatic cuff at 30-40% of arterial occlusion pressure. Resistance exercises will be performed at 30% of one-repetition maximum (1RM) using a 4-set protocol (30-15-15-15 repetitions) with 45-second inter-set rest periods while maintaining cuff pressure. Target muscles include the biceps brachii, triceps brachii, and anterior deltoid.

  • OtherSham Low-Load Blood Flow Restriction Training (LL-BFRT) + Aerobic Exercise

    Participants will undergo the same 8-week upper extremity aerobic exercise program as the intervention group. Aerobic exercise will be performed using an arm cycle ergometer at 60-70% of age-predicted maximum heart rate for 20 minutes, preceded and followed by 5 minutes of unloaded cycling. In addition, sham blood flow restriction training will be applied with a pneumatic cuff placed proximally on the upper extremity. The cuff pressure will be set at a level insufficient to produce therapeutic blood flow restriction. The exercise structure, sets, repetitions, and muscle groups targeted will be identical to the intervention group.

06

What researchers measure

Primary outcomes

  1. Upper Extremity Functional Capacity

    Upper extremity functional capacity and endurance will be assessed using the 6-Minute Pegboard \& Ring Test (6-PBRT). During the test, participants will be seated in front of a pegboard and instructed to use both hands simultaneously to transfer as many rings as possible from two lower pegboards positioned at shoulder level to two upper pegboards located 20 cm above, and then back to the lower boards. The test duration is 6 minutes. Prior to the actual test, participants will be allowed to practice by transferring a few rings to familiarize themselves with the procedure. During the test, the physiotherapist will provide standardized verbal encouragement every minute to motivate the participant. At the end of the 6 minutes, the total number of rings transferred throughout the test will be recorded as the final score (16).

    Time frame: Pre- and post-intervention (week 8).

Secondary outcomes

  1. Pulmonary Function Assessment

    Pulmonary function will be assessed using spirometric measurements. Spirometry is a standard pulmonary function test that evaluates lung volume and airflow rates. During the test, participants will be instructed to exhale forcefully and completely to achieve maximal lung emptying. Parameters including Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), and the FEV1/FVC ratio will be recorded. In addition, post-bronchodilator FEV1/FVC \< 0.70 will be used for diagnosis and classification in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (18).

    Time frame: Pre- and post-intervention (week 8).

  2. Muscle Strength Assestment

    Muscle strength of the biceps brachii, triceps brachii, and anterior deltoid muscles will be assessed using a Hand-Held Dynamometer (HHD). Measurements will be performed in standardized seated positions at specific joint angles. Biceps brachii strength will be measured with the elbow flexed at 90° and the forearm in supination (19). Triceps brachii strength will be measured during maximal isometric elbow extension, and anterior deltoid strength during shoulder flexion at 90°. Three measurements will be taken for each muscle group and the highest value will be recorded for analysis.

    Time frame: Pre-post ıntervention (week 8)

  3. Activity Of Daily Living Assestment

    Activities of daily living will be evaluated using the Londrina Activities of Daily Living (Londrina ADL) Scale. This protocol includes five activities involving upper and lower extremity movements as well as trunk flexion, inclination, and rotation. Participants will sit in front of a table and transfer ten objects of different weights (250 g, 500 g, and 1 kg) from one side of the table to the other using both hands and then return them to the initial position. Participants will also walk three consecutive times over a 6-meter distance as part of the protocol. The total time required to complete all activities will be recorded as the outcome measure.

    Time frame: Pre-post ıntervention (week 8)

  4. Quality Of Life Assestment

    Quality of life will be assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a disease-specific quality of life instrument consisting of 50 items and three domains. The Symptoms domain evaluates the frequency and severity of respiratory symptoms; the Activity domain assesses the impact of respiratory problems on daily activities; and the Impacts domain measures the psychosocial and functional effects of the disease on the individual's life. Response options for the items range between 2 and 5 points, and each item is weighted according to its predefined scoring algorithm during calculation (23).

    Time frame: Pre-post ıntervention (week 8)

  5. Functional Capacity

    Functional capacity will be assessed using the 6-Minute Walk Test (6MWT). Participants will be instructed to walk as far as possible for 6 minutes, and standardized verbal encouragement will be provided every minute throughout the test. Participants will be allowed to rest as needed; however, they will be encouraged to resume walking as soon as possible. Individuals requiring long-term oxygen therapy or those with resting hypoxemia may receive their usual oxygen flow during the test. Oxygen saturation will be continuously monitored using pulse oximetry (SpO₂) via a finger probe throughout the test. At the end of the test, the total walking distance will be recorded (24).

    Time frame: Pre-post ıntervention (week 8)

  6. Muscle Oxygenation Measurement

    Muscle oxygenation will be assessed using the Moxy Monitor, a portable device based on near-infrared spectroscopy technology. The device emits light waves into the tissue and detects scattered light using photodetectors placed at different distances from the light source. The detected signal is analyzed using an algorithm based on the Beer-Lambert law to determine oxygenated and deoxygenated hemoglobin levels, allowing the calculation of total hemoglobin (THb) and muscle oxygen saturation (SmO₂). Since light entering larger microvessels is assumed to be fully absorbed, the detected signal mainly originates from capillaries; therefore, the measurements reflect local muscle oxygenation and microvascular oxygen utilization.

    Time frame: Pre-post ıntervention (week 8)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Crum EM, O'Connor WJ, Van Loo L, Valckx M, Stannard SR. Validity and reliability of the Moxy oxygen monitor during incremental cycling exercise. Eur J Sport Sci. 2017 Sep;17(8):1037-1043. doi: 10.1080/17461391.2017.1330899. Epub 2017 May 30. PubMed 28557670 ↗
  • Huang CT, Ruan SY, Tsai YJ, Chien JY, Yu CJ. Lung fluid content during 6MWT in patients with COPD with and without comorbid heart failure. BMJ Open Respir Res. 2024 Mar 30;11(1):e002000. doi: 10.1136/bmjresp-2023-002000. PubMed 38555101 ↗
  • Liang WM, Chen JJ, Chang CH, Chen HW, Chen SL, Hang LW, Wang JD. An empirical comparison of the WHOQOL-BREF and the SGRQ among patients with COPD. Qual Life Res. 2008 Jun;17(5):793-800. doi: 10.1007/s11136-008-9326-5. Epub 2008 May 24. PubMed 18500580 ↗
  • Deshpande C, Alaparthi GK, Krishnan S, Chakravarthy Bairapareddy K, Ramakrishna A, Acharya V. Comparison of Londrina activities of daily living protocol and Glittre ADL test on cardio-pulmonary response in patients with COPD: a cross-sectional study. Multidiscip Respir Med. 2020 Dec 4;15(1):694. doi: 10.4081/mrm.2020.694. eCollection 2020 Jan 28. PubMed 33324483 ↗
  • Chamorro C, Arancibia M, Trigo B, Arias-Poblete L, Jerez-Mayorga D. Absolute Reliability and Concurrent Validity of Hand-Held Dynamometry in Shoulder Rotator Strength Assessment: Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2021 Sep 3;18(17):9293. doi: 10.3390/ijerph18179293. PubMed 34501883 ↗
  • Johanson ME, Lateva ZC, Jaramillo J, Kiratli BJ, McGill KC. Triceps Brachii in Incomplete Tetraplegia: EMG and Dynamometer Evaluation of Residual Motor Resources and Capacity for Strengthening. Top Spinal Cord Inj Rehabil. 2013 Fall;19(4):300-10. doi: 10.1310/sci1904-300. PubMed 24244095 ↗
  • Yesilyaprak SS, Ozden F. An acute bout of foam rolling of the biceps brachii does not affect upper extremity sensorimotor function: a randomized trial. BMC Musculoskelet Disord. 2025 Nov 13;26(1):1044. doi: 10.1186/s12891-025-09173-y. PubMed 41233773 ↗
  • Arne M, Lisspers K, Stallberg B, Boman G, Hedenstrom H, Janson C, Emtner M. How often is diagnosis of COPD confirmed with spirometry? Respir Med. 2010 Apr;104(4):550-6. doi: 10.1016/j.rmed.2009.10.023. PubMed 19931443 ↗
  • Oncu H, Calik-Kutukcu E, Vardar Yagli N, Inal-Ince D, Saglam M, Unal F, Aksoy S. Reliability and validity of the 6-minute pegboard and ring test for functional exercise capacity in patients with breast cancer. Physiother Theory Pract. 2025 Mar;41(3):643-655. doi: 10.1080/09593985.2024.2353260. Epub 2024 May 13. PubMed 38739486 ↗
  • Calik-Kutukcu E, Tekerlek H, Bozdemir-Ozel C, Karaduz BN, Cakmak A, Inal-Ince D, Saglam M, Vardar-Yagli N, Sonbahar-Ulu H, Firat M, Arikan H, Kaya SB, Karakaya G. Validity and reliability of 6-minute pegboard and ring test in patients with asthma. J Asthma. 2022 Jul;59(7):1387-1395. doi: 10.1080/02770903.2021.1930040. Epub 2021 May 31. PubMed 33985406 ↗
  • Janaudis-Ferreira T, Hill K, Goldstein RS, Wadell K, Brooks D. Relationship and responsiveness of three upper-limb tests in patients with chronic obstructive pulmonary disease. Physiother Can. 2013 Winter;65(1):40-3. doi: 10.3138/ptc.2011-49. PubMed 24381380 ↗
  • Fabero-Garrido R, Gragera-Vela M, Del Corral T, Hernandez-Martin M, Plaza-Manzano G, Lopez-de-Uralde-Villanueva I. Effects of Low-Load Blood Flow Restriction Training on Muscle Anabolism Biomarkers and Thrombotic Biomarkers Compared with Traditional Training in Healthy Adults Older Than 60 Years: Systematic Review and Meta-Analysis. Life (Basel). 2024 Mar 20;14(3):411. doi: 10.3390/life14030411. PubMed 38541735 ↗
  • Lin Q, Zhang Y, Qin J, Wu F. Effects of Low-Load Blood Flow Restriction Training on Muscle Volume After Anterior Cruciate Ligament Reconstruction: A Systematic Review and Meta-analysis. Orthop J Sports Med. 2024 Dec 13;12(12):23259671241301731. doi: 10.1177/23259671241301731. eCollection 2024 Dec. PubMed 39678440 ↗
  • Kohlbrenner D, Kuhn M, Manettas A, Aregger C, Peterer M, Greco N, Sievi NA, Clarenbach C. Low-load blood flow restriction strength training in patients with COPD: a randomised single-blind pilot study. Thorax. 2024 Mar 15;79(4):340-348. doi: 10.1136/thorax-2023-220546. PubMed 38129116 ↗
  • Pancera S, Lopomo NF, Porta R, Sanniti A, Buraschi R, Bianchi LNC. Effects of Combined Endurance and Resistance Eccentric Training on Muscle Function and Functional Performance in Patients With Chronic Obstructive Pulmonary Disease: Randomized Controlled Trial. Arch Phys Med Rehabil. 2024 Mar;105(3):470-479. doi: 10.1016/j.apmr.2023.09.004. Epub 2023 Sep 15. PubMed 37716519 ↗
  • Kohlbrenner D, Aregger C, Osswald M, Sievi NA, Clarenbach CF. Blood-Flow-Restricted Strength Training Combined With High-Load Strength and Endurance Training in Pulmonary Rehabilitation for COPD: A Case Report. Phys Ther. 2021 Jun 1;101(6):pzab063. doi: 10.1093/ptj/pzab063. PubMed 33580965 ↗
  • Panton LB, Golden J, Broeder CE, Browder KD, Cestaro-Seifer DJ, Seifer FD. The effects of resistance training on functional outcomes in patients with chronic obstructive pulmonary disease. Eur J Appl Physiol. 2004 Apr;91(4):443-9. doi: 10.1007/s00421-003-1008-y. Epub 2003 Nov 25. PubMed 14639479 ↗
  • Gloeckl R, Pitta F, Nyberg A. Optimising upper-limb exercise in patients with COPD: another step towards personalised pulmonary rehabilitation? ERJ Open Res. 2024 Feb 26;10(1):01012-2023. doi: 10.1183/23120541.01012-2023. eCollection 2024 Jan. PubMed 38410717 ↗
  • Ozsoy I, Ozcan Kahraman B, Ozsoy G, Ilcin N, Kahraman T, Acar S, Tekin N, Savci S. Determinants of the 6-minute pegboard and ring test as an unsupported upper-extremity exercise capacity measure in older adults with chronic obstructive pulmonary disease. Eur Geriatr Med. 2018 Dec;9(6):863-870. doi: 10.1007/s41999-018-0111-x. Epub 2018 Sep 25. PubMed 34674474 ↗
  • McKeough ZJ, Velloso M, Lima VP, Alison JA. Upper limb exercise training for COPD. Cochrane Database Syst Rev. 2016 Nov 15;11(11):CD011434. doi: 10.1002/14651858.CD011434.pub2. PubMed 27846347 ↗
  • Dag B, Naz I, Felekoglu E, Emuk Y, Kopruluoglu M, Sahin H. Associations of Upper-Extremity Exercise Capacity and Grip Strength With Cognitive Domains in Patients With COPD. Respir Care. 2024 Apr 22;69(5):595-602. doi: 10.4187/respcare.11610. PubMed 38378201 ↗
  • Fonseca J, Nellessen AG, Pitta F. Muscle Dysfunction in Smokers and Patients With Mild COPD: A SYSTEMATIC REVIEW. J Cardiopulm Rehabil Prev. 2019 Jul;39(4):241-252. doi: 10.1097/HCR.0000000000000400. PubMed 30870243 ↗
  • Wada JT, Borges-Santos E, Porras DC, Paisani DM, Cukier A, Lunardi AC, Carvalho CR. Effects of aerobic training combined with respiratory muscle stretching on the functional exercise capacity and thoracoabdominal kinematics in patients with COPD: a randomized and controlled trial. Int J Chron Obstruct Pulmon Dis. 2016 Oct 28;11:2691-2700. doi: 10.2147/COPD.S114548. eCollection 2016. PubMed 27822031 ↗
  • Zhang L, Liu Y, Zhao S, Wang Z, Zhang M, Zhang S, Wang X, Zhang S, Zhang W, Hao L, Jiao G. The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis. 2022 Jun 10;17:1365-1379. doi: 10.2147/COPD.S359873. eCollection 2022. PubMed 35711174 ↗
  • Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, Lopez Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP. PubMed 28128970 ↗

Individual participant data

Plan to share: No — Participant data will be securely stored by the investigators and may be shared with authorized personnel if deemed necessary, in accordance with applicable privacy regulations.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Dec 2026, 10 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 10 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2026
First posted
Mar 13, 2026
StartEst.
Feb 15, 2026
Primary completionEst.
Dec 25, 2026
CompletionEst.
Dec 25, 2026
Last update
Mar 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07469111
Lead sponsor
Inonu University
Responsible party
Zeynal Yasacı (Doctor Lecturer, Inonu University) — Principal investigator
First posted
Mar 13, 2026
Start date
Feb 15, 2026 (estimated)
Primary completion
Dec 25, 2026 (estimated)
Completion
Dec 25, 2026 (estimated)
Last update
Mar 13, 2026

Study contacts

Zeynal Yasacı, Doctor Lecturer
Contact
zeynal.yasaci@inonu.edu.tr
+905075409791
Emine Tonak
Contact
eminetonak4006@gmail.com
+905372994319

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion